PRIVA-RIVASTIGMINE PATCH
Nchi: Kanada
Lugha: Kiingereza
Chanzo: Health Canada
Tabia za bidhaa
(SPC)
05-07-2019
Hati zingine za bidhaa hii hazipatikani kwa sasa, unaweza kutuma ombi kwa huduma ya wateja wetu na tutakuarifu mara tu tutakapopata.
Tuma ombi.
Tuma ombi.
Viambatanisho vya kazi:
RIVASTIGMINE
Inapatikana kutoka:
PHARMAPAR INC
ATC kanuni:
N06DA03
INN (Jina la Kimataifa):
RIVASTIGMINE
Kipimo:
4.6MG
Dawa fomu:
PATCH
Tungo:
RIVASTIGMINE 4.6MG
Njia ya uendeshaji:
TRANSDERMAL
Vitengo katika mfuko:
100
Dawa ya aina:
Prescription
Eneo la matibabu:
PARASYMPATHOMEMETIC (CHOLINERGIC) AGENTS
Bidhaa muhtasari:
Active ingredient group (AIG) number: 0140521007; AHFS:
Idhini hali ya:
CANCELLED PRE MARKET
Idhini ya tarehe:
2021-07-05
Tabia za bidhaa
_Page 1 of 63_
PRODUCT MONOGRAPH
PR
PRIVA-RIVASTIGMINE
Rivastigmine Transdermal Patch
Each patch of 5 cm
2
contains 9 mg rivastigmine, _in vivo _release rate of 4.6 mg/24 h
Each patch of 10 cm
2
contains 18 mg rivastigmine, _in vivo _release rate of 9.5 mg/24 h
Each patch of 15 cm
2
contains 27 mg rivastigmine, _in vivo _release rate of 13.3 mg/24 h
Cholinesterase Inhibitor
DATE OF
PREPARATION:
July 5, 2019
Pharmapar Inc.
1565 Boul. Lionel-Boulet
Varennes, Quebec
J3X 1P7
www.pharmapar.ca
CONTROL NO.: 228274
_Page 2 of 63_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................... 3
SUMMARY PRODUCT INFORMATION
.........................................................................
3
INDICATIONS AND CLINICAL USE
...............................................................................
3
CONTRAINDICATIONS
....................................................................................................
3
WARNINGS AND PRECAUTIONS
...................................................................................
4
ADVERSE REACTIONS
...................................................................................................
12
DRUG INTERACTIONS
...................................................................................................
24
DOSAGE AND ADMINISTRATION
...............................................................................
25
OVERDOSAGE
.................................................................................................................
28
ACTION AND CLINICAL PHARMACOLOGY
............................................................. 28
STORAGE AND STABILITY
...........................................................................................
33
SPECIAL HANDLING INSTRUCTIONS
........................................................................
33
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................. 33
PART II: SCIENTIFIC INFORMATION
...............................
Soma hati kamili
